Lannett Company, Inc. (LCI) was a big mover last session with its shares rising over 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the uptrend of the company as the stock has gained nearly 28% since Feb 6.
This pharmaceutical company has seen four positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved considerably higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if yesterday’s price action can turn into more strength down the road.
Lannett Company currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.
Other top-ranked Med-Drug stocks include Endocyte, Inc. (ECYT), Ariad Pharmaceuticals Inc. (ARIA) and BioCryst Pharmaceuticals, Inc. (BCRX). While ARIA and BCRX carry a Zacks Rank #2 (Buy), ECYT sports the same Zacks Rank as Lannett.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
LANNETT COMP (LCI): Free Stock Analysis Report
ENDOCYTE INC (ECYT): Free Stock Analysis Report
ARIAD PHARMACEUTICALS INC (ARIA): Free Stock Analysis Report
BIOCRYST PHARMACEUTICALS INC (BCRX): Free Stock Analysis Report
Zacks Investment Research